The US Bankruptcy Court gave an order approving the sale of the certain assets of Codiak BioSciences, Inc. on June 6, 2023. The debtor has been authorized to sell its certain assets to Evox Therapeutics Ltd. for a purchase price of $2.1 million in cash plus the assumption of Assumed Liabilities pursuant to the asset purchase agreement. The debtor’s assets include Scheduled Patents, Seller’s inbound licenses for Intellectual Property, the Trademarks, Books and Records, Assigned Contracts, Purchased Inventory, and all goodwill associated with any of the Acquired Assets.

Under the terms of the asset purchase agreement, the buyer has made an earnest money deposit of $0.21 million upon the execution of the agreement. The buyer is represented by Michael Klein, Lauren Reichardt, and Michal Berkner Cooley LLP as its legal counsel.